Search
Showing results for "Childhood interstitial lung disease "
Learn how research with Aboriginal communities is saving young hearts across Australia.
Pseudomonas aeruginosa Resistance to Bacteriophages and Its Prevention by Strategic Therapeutic Cocktail Formulation Antimicrobial resistance poses a
An adapted novel flow cytometry methodology to delineate types of cell death in airway epithelial cells Cystic fibrosis (CF) lung disease is
Lack of small colony variants of Staphylococcus aureus from lower respiratory tract specimens Abstract Background: Small-colony variants (SCVs) of
A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.
In mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.
Environmental factors including household crowding and inadequate washing facilities underpin recurrent streptococcal infections in childhood that cause acute rheumatic fever (ARF) and subsequent rheumatic heart disease (RHD).
No new safety concerns were identified for live attenuated herpes zoster vaccine in this study based on a novel, Australian primary care data source
A biologically active vaccine may produce a low measured vaccine efficacy under a range of epidemiological, vaccine-related and logistical conditions
Nurses consider antimicrobial stewardship activities within their roles, but are underutilised in antimicrobial stewardship programs